The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study). SWOG; Papadimitrakopoulou, Vassiliki A. (713) 792-6363
AAML15B6-Q: Use of DNA Methylation Assessment by xMELP for Prognosis in Pediatric Patients with Acute Myeloid Leukemia. Children’s Oncology Group Wertheim, Gerald. (267) 970-5918
ANBL14B4-Q: Correlation Between Tumor Stage and MXI1 & MXI0 Expression in Neuroblastoma Tumor Samples. Children’s Oncology Group; Armstrong, Michael Brannon. (919) 684-3401
ANBL14B6-Q: Development of a miRNA Serum Signature for Minimally Invasive and Accurate Outcome Prediction of High-Risk Neuroblastoma Patients. Children’s Oncology Group; Vandesompele, Jo. 32 9 332 5187
ARST15B1-Q: Genetic Susceptibility in Rhabdomyosarcoma. Children’s Oncology Group; Lupo, Philip. (713) 798-2960